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ABSTRACT 
Minimally invasive endovascular embolization procedures decrease surgery time, speed up 
recovery, and provide the possibility for more comprehensive treatment of aneurysms, 
arteriovenous malformations (AVMs), and hypervascular tumors. Liquid embolic agents 
(LEAs) are preferred over mechanical embolic agents, such as coils, because they achieve 
homogeneous filling of aneurysms and more complex angioarchitectures. The gold 
standard of commercially available LEAs is dissolved in dimethyl sulfoxide (DMSO), 
which has been associated with vasospasm and angiotoxicity. The aim of this study was to 
investigate amino acid substitution in an enzyme-degradable side group of an N-
isopropylacrylamide (NIPAAm) copolymer for the development of a LEA that would be 
delivered in water and degrade at the rate that tissue is regenerated. NIPAAm copolymers 
have a lower critical solution temperature (LCST) due to their amphiphilic nature. This 
property enables them to be delivered as liquids through a microcatheter below their LCST 
and to solidify in situ above the LCST, which would result in the successful selective 
occlusion of blood vessels. Therefore, in this work, a series of poly(NIPAAm-co-peptide) 
copolymers with hydrophobic side groups containing the Ala-Pro-Gly-Leu collagenase 
substrate peptide sequence were synthesized as in situ forming, injectable copolymers.. 
The Gly-Leu peptide bond in these polypeptides is cleaved by collagenase, converting the 
side group into the more hydrophilic Gly-Ala-Pro-Gly-COOH (GAPG-COOH), thus 
increasing the LCST of the hydrogel after enzyme degradation. Enzyme degradation 
property and moderate mechanical stability convinces the use of these copolymers as liquid 
embolic agents.  
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
1.1. A Brief History of Endovascular Embolization 
Endovascular treatment decreases hospitalization time and speeds-up recovery as 
compared to open surgery.1 The first reported embolization of head and neck cancers was 
made by Dawbarn with paraffin particles in 1904.2 Later, Luessenhop and Spence 
performed the first reported cerebral arteriovascular malformation (AVM) embolization 
with silastic beads in 1960.3 In 1971, Servinenko in Russia was the first to use detachable 
balloons.4 The main disadvantage of detachable balloons, however, was that they deflated 
over time. The earliest CT scanner used to visualize the circulatory system as a tool to 
diagnose and treat blood vessel disease was first used for brain imaging in 1972.5 Since 
then, advancements in technology have facilitated the minimally invasive delivery of liquid 
embolic agents. It was common procedure to puncture the surgically exposed carotid artery 
until Djindjan et al. in France in 1973 and Kricheff et al. in the USA in 1972 used the 
transfemoral route for catheter embolization.6,7 Catheter-directed transarterial embolization 
was first reported in 1972 by Charles Dotter’s group in the USA.8 In 1975, Hilal and 
Michelsen used low-viscosity silicone polymer for the embolization of vascular tumors.9 
Cyanoacrylate glues that undergo polymerization in presence of blood were 
commercialized in the 1970s and have been used since then for the treatment of AVMs.10 
Cromwell and Kerber developed a balloon catheter that would enable the delivery of 
acrylic glue in a brain AVM without reflux and published his results in 1979.11 Other 
embolic agents used in that time included Gelfoam®, silicone spheres, poly(vinyl alcohol) 
(PVA), and Ethibloc®.12 Ethibloc®, no longer on the market, is a liquid embolic agent that 
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consists of a protein derived from maize and dissolved in Lipiodol® or additional alcohol, 
used predominantly for the embolization of vascular tumors and AVMs.12 Coils for 
endovascular embolization were first introduced as small pieces of guidewire without the 
inner core, known as Gianturco coils, in 1975.13 Later, more flexible platinum coils were 
developed; Guglielmi et al. introduced retrievable electrolytic detachable coils for cerebral 
aneurysms in 1991.14 Currently, mechanical detachable coils are the gold standard for 
embolization procedures.12  
1.2. Overview of Liquid Embolic Agents 
The delivery of liquid embolics is done minimally invasively through a microcatheter that 
goes from the femoral artery into a feeding pedicle of an AVM, hypervascular tumor, or to 
the aneurysm site. Liquid embolics achieve homogeneous filling of aneurysms and more 
complex angioarchitectures present in vascular malformations and hypervascular tumors. 
Recanalization is also less common when using liquid embolics as compared to coils.12 A 
shortcoming of embolic agents is the limited ability to penetrate the arterial vascular 
network as it increases in number of branches that gradually decrease in caliber, often 
resulting in incomplete embolization of AVMs.15 
The distance traveled by liquid embolic agents depends on several factors, 
including viscosity, rate of injection, and microcatheter position.16 Some liquid embolic 
agents are available in several concentrations with different viscosities. The lower viscosity 
formulations will travel more distally and penetrate deeper.17 In some cases, it is 
appropriate to use a combination of different formulations for the same procedure. 
Embolization techniques include transvenous embolization with proximal balloon-
protection, transarterial embolization and direct puncture. Precipitating liquid embolics 
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commercially available are typically dissolved in dimethyl sulfoxide (DMSO) or ethanol. 
Upon injection, the solvent dissipates with blood, causing the polymer to precipitate in situ 
into an embolus.16,17  
1.3. Clinical Applications of Liquid Embolic Agents 
1.3.1. High-flow Vascular Malformations 
About 60,000 people have a high-flow vascular malformation in U.S. and around 240 will 
experience a hemorrhage, which presents a 15 to 20% risk of death or stroke and 30% 
neurological morbidity.18 There are two types of vascular malformations that are treated 
by embolization: arteriovenous malformations, and arteriovenous fistulas.19 Both types of 
vascular malformations present similar challenges in treatment. 19,20 Normally, blood flows 
from arteries to capillaries to veins. Capillaries serve to dampen blood pressure as it flows 
from arteries to veins. Arteriovenous malformations (AVMs) consist of feeding arteries, a 
network of small pathologic vessels in place of capillaries also referred to as the nidus, and 
draining veins.21 AVMs often have several feeding arteries that supply blood to the nidus, 
also known as feeding pedicles that require embolization prior to resection.22 
Arteriovenous fistulas (AVFs) are abnormal connections between arteries and veins 
without the presence of a nidus or capillaries.19 The absence of capillaries results in high-
pressure blood flow into veins, which causes them to widen and often leads to rupture of 
the vessel wall. Cerebral AVMs may cause morbidity, neurological deficit and present a 
risk of hemorrhaging. 21 AVMs can be treated by transarterial embolization, transvenous 
embolization, direct puncture embolization, stereotactic radiosurgery, and surgical 
excision, alone or in combination. 15 
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Surgical resection is recommended for the management of AVMs. Pre-surgical 
embolization is meant to ease surgical removal, decrease surgery complications and reduce 
blood loss during surgery. 12,23 The goal of endovascular embolization of AVMs is the 
closure of the whole nidus without occluding other surrounding vessels. 12,23 Successful 
penetration into the nidus and draining vein requires the microcatheter to be positioned less 
than 1cm from the nidus, which often cannot be achieved.22 In such cases, occlusion of the 
arterial supply is sufficient if the AVM is surgically accessible for subsequent resection . 
17,20,23 Incomplete resection or embolization may lead to further angiogenesis, which could 
increase the angioarchitecture complexity, thus making its subsequent treatment more 
challenging.15 For example, angiogenesis may manifest as the creation of new feeders that 
may be too narrow to allow microcatheter access in subsequent treatment.15  
A challenge that remains with AVFs when embolization is not accompanied by 
resection is that is that their high-flow nature has been reported to cause embolic materials 
to migrate into the distal draining veins, potentially resulting in unintentional pulmonary 
embolization.15,20 Similarly, reflux of liquid embolics into the distal venous drainage or 
proximal arteries during embolization is often difficult to control and should be prevented. 
Surgical resection is necessary if venous drainage is observed.15,24   
Some AVFs that have been reported to be treated successfully by endovascular 
embolization include dural, brain, and scalp arteriovenous fistulas. Dural arteriovenous 
fistulas (dAVFs) within the dura mater of the brain represent 10-15% of all intracranial 
AVMs.17,25 They may present some disabling symptoms, and hemorrhage occurs in about 
65% of patients.25 Congenital brain arteriovenous fistulas account for 1.6 to 4.7% of all 
brain AVMs and are characterized by the absence of a nidus and their high-flow nature.20  
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Although they can be asymptomatic, they can also produce seizures, hemorrhage, increased 
intracranial pressure, among other symptoms that make treatment necessary.20,21 The large 
draining vein can interfere with the exposure of the fistula making surgery challenging and 
not ideal. 20 Endovascular management facilitates localization of the lesion and enables 
access to deep and/or critical areas. 20 The heterogeneous angioarchitecture of scalp AVFs 
and non-uniform structure makes them challenging to treat.15 Their high-flow shunting can 
lead to blood loss if the fistula is punctured during resection, for which endovascular 
management is generally recommended.15  
1.3.2. Aneurysms 
It is estimated that 6 million people in the United States have one or more unruptured brain 
aneurysms each year, 10% of which need treatment.26 About 30,000 people in the U.S. 
suffer an aneurysm rupture each year, which can result in death in 40% of the cases, or 
permanent neurological deficit in 70% of those who survive.26 The objective of treating 
aneurysms is their complete and permanent occlusion.27 Ideally, this would be 
accompanied by the remodelling of the parent artery.  
Saccular aneurysms are the most common type of intracranial aneurysm. They 
consist of a sac-like “dome” and a “neck” connected to one side of the parent artery wall 
or one of its main branches. LEAs achieve homogeneous and complete filling of aneurysms 
as opposed to coils. The use of platinum coils to treat large, wide-necked intracranial 
aneurysms often requires repeat treatment due to coil compaction as well as the use of a 
stent to prevent migration to nearby vessels.27,28 Infectious aneurysms are also greatly 
benefitted from treatment with LEAs. Aneurysms with inflamed vascular tissue cannot be 
treated by surgical clipping due to the risk of clip erosion. Furthermore, infectious 
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aneurysms are often irregular in shape making endovascular embolization with LEAs 
ideal.29 
The most common complication after endovascular aneurysm repair are type II 
endoleaks, characterized by the persistent perfusion within the aneurysmal sac and occur 
in 10 to 30% of patients.16,30 Complex type II endoleaks may have a nidus as well as feeding 
and draining vessels.30 Patients require follow-up CT imaging to assess the aneurysm sac 
size, size of the nidus, diameter of the feeding and draining vessels and the diameter of the 
feeding collateral artery to determine if intervention is necessary.30  
1.3.3. Hypervascular Tumors 
Presurgical endovascular embolization of hypervascular tumors has proven to mitigate 
blood loss, operative times and infection rates from surgical resection.31,32 In addition, it 
may decrease surgical morbidity and mortality.33 Some studies have pointed out the high 
associated cost of preoperative embolization of hypervascular tumors due to the large 
volume required for complete devascularization. 31 However, advantages of preoperative 
embolization, in addition to the low complication rate, have increased its preference.31 For 
example, some physicians have reported that anterior skull based meningiomas fed by the 
ophthalmic artery benefit from embolization by reducing the risk of visual impairment.33 
Usually devascularization is performed using polyvinyl alcohol (PVA) 
microparticles. 32 When the feeders to the metastatic region also supply the anterior spinal 
artery, which is the case for spinal hypervascular tumors, there is a risk that microparticles 
will migrate, posing a high risk of neurological complication.32 When the vessels are small 
and tortuous, they may not be accessible by microcatheterization.32 In such cases, direct 
puncture of the lesion is recommended to administer microparticles or LEAs if surgically 
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accessible.32 Alternatively, injection of Onyx®, the leading liquid embolic agent, by 
endovascular route or by direct puncture has been used to successfully devascularize 
hypervascular tumors while providing a low risk of uncontrolled migration.32 
1.4 Commercially Available Liquid Embolic Agents 
1.4.1. N-Butyl Cyanoacrylate (NBCA) 
NBCA (Trufill®, Cordis, Miami Lakes, Fl), also known as glue, is a nonabsorbable, 
adhesive embolic agent that polymerizes into a hard mass upon contact with ionic fluid and 
mixed with tantalum or tungsten powder for radioopacity.12,15,25,29 It was approved by the 
FDA in 2000 for the treatment of brain AVMs.34 It consists of 1 g tubes of NBCA, 10 mL 
of ethiodized oil, and 1 g of tantalum powder, all mixed before use.35 Due to its rapid 
polymerization, it is necessary to rinse the microcatheter with a nonionic solution, such as 
a dextrose solution, prior to delivery to prevent microcatheter occlusion. 12,29 Rapid 
injection should be avoided because it could lead to retrograde embolization that could lead 
to microcatheter entrapment.12 Ethiodized oil, such as Lipiodol, has been used to control 
the rate of polymerization.12 However, even at high lipiodol dilution, it is unable penetrate 
the small feeding pedicles in an AVM before turning into a hard mass.15 Another 
disadvantage of NBCA is its lack of biocompatibility, thus causing a significant vascular 
inflammatory reaction that can lead to angionecrosis. 15,36,37 Furthermore, it presents a high 
risk of recanalization; the largest study for dAVFs embolized with NBCA showed that only 
33% of patients had complete occlusion at the 3-month postprocedure visit.12,17 
1.4.2. Onyx® 
Onyx® (Medtronic, Irvine, California) is a non-adhesive liquid embolic agent introduced 
in 1990 and approved by the FDA for endovascular treatment of AVMs in 2005 and the 
  
8 
leading LEA in the market.21,24,25,38 It is composed of 67 mol% polyethylene (PE) and 33 
mol% polyvinyl alcohol (PVA), commonly referred to as ethylene-vinyl alcohol (EVOH), 
and micronized tantalum for radioopacity dissolved in dimethyl-sulfoxide 
(DMSO).1,12,23,25,39 PE is hydrophobic and PVA is hydrophilic, so Onyx® has both 
properties, which contribute to its cohesiveness.24 Onyx ®18, 20, 34 and Onyx®-HD 500 
(numbers indicating viscosity in centistokes) contain 6%, 6.5%, 8%, and 20% EVOH, 
respectively.21,27,30,40 Onyx® HD-500+ contains 20% EVOH, but with higher tantalum 
concentration.27 It is supplied as two 1.5 mL glass vials, one containing EVOH plus 
tantalum and the other one containing DMSO.41 
All formulations require shaking for at least 20 minutes before injection to achieve 
a homogeneous solution.21,23 Prior to delivering EVOH, 2 ml of DMSO are injected to 
irrigate the catheter lumen in order to prevent the copolymer from solidifying before 
reaching the embolization site.24 The polymer precipitates in situ when it contacts blood as 
the solvent diffuses from the mixture and solidifies completely over a period of about 10 
minutes, resulting in a pliable, rubbery, spongy, compressible material.1,12,15,23,30,31,39  
Complete filling with Onyx® is achievable, but antiplatelet therapy is necessary due to the 
risk of having small portions of the material pass into the parent artery. 27,40 
Onyx® 18, 20, and 34 are approved for the presurgical embolization of intracranial 
AVMs. 40 Onyx® 18 is often used in combination with Onyx® 34 for the treatment of 
AVMs, AVFs and type II endoleaks.15,30 Successful treatment of dAVFs has been reported 
extensively in literature with up to 80% complete occlusion rate at the 3-month post-
procedure follow-up.17,25,42 Onyx® has also been used in combination with coils in the 
treatment of AVFs.20 Detachable coils provide a template for Onyx® deposition, create 
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turbulent flow that promotes diffusion, and provide a physical barrier that minimizes the 
risk of distal embolization.20 Onyx® 18 and 34 have also been administered off-label with 
good results by endovascular route for the embolization of spinal hemangioma, juvenile 
nasopharyngeal angiofibromas, paragangliomas and  meningiomas, among other head and 
neck tumors.32,43 In addition, it has produced satisfactory results by direct puncture for 
several skull base, head and neck tumors.32 
Onyx® HD-500, designed to fill large or giant aneurysms, is FDA approved for the 
treatment of broad-base, sidewall, intracranial aneurysms.27,40 Onyx® HD-500 has also 
been used for the immediate and complete occlusion a large ruptured intracranial 
pseudoaneurysm arising from a large, proximal intracranial artery, without the need for 
vessel sacrifice.40 However, the treatment of unruptured saccular aneurysms with Onyx® 
is associated with up to 15.7% permanent morbidity and up to 4% mortality.27 The 
mortality rate increases to over 20% for giant aneurysms.27  
Advantages of Onyx® as compared to NBCA are its more permanent nature, low 
viscosity, non-adhesiveness and delayed precipitation, which allows for a slower, more 
deliberate delivery and better penetration.21,30,31 Controlled administration, propagation, 
and gradual centripetal precipitation allows for a better chance to completely embolize the 
nidus as well as the feeding and draining vessels in AVMs.1,30,31 A study showed that, due 
to its better penetration, the chance of not requiring surgical resection post-embolization 
was 81.8% with Onyx® versus 22.22% with NBCA.44 However, although Onyx® 18 has a 
high ability to penetrate up to 5 micrometer diameter vessels, it is also more likely to reflux 
proximally from the microcatheter tip. 15,45 Excessive reflux along the catheter could lead 
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to unwanted occlusion of more proximal vessels.39 In addition, catheter entrapment could 
occur if left in contact with the embolic agent for too long. 24,39  
There are also some issues associated with tantalum in Onyx®. Tantalum has a 
tendency to aggregate, which may result in microcatheter blockage.39 It also poses a risk 
of sparking and combustion during subsequent surgical resection of AVMs when exposed 
to mono-polar diathermy, monopolar cautery, or high-energy bipolar cautery.15,16,21,46 In 
addition, large amounts of Onyx® could result in dense radio-opaque saturation that 
decreases visibility.23 Post-operative assessment is challenging because Onyx® produces 
significant streak artifacts on CT scans, gradient recalled-echo (GRE) and susceptibility-
weighed imaging (SWI) sequences. 16,23,30 In addition, the dark color of tantalum limits its 
use for facial AVMs due to tattoo effect.23  
There are also several disadvantages associated with DMSO. After successful 
procedures, some patients have reported nausea, headache and a strong garlic-like odor 
from their breath and/or sweat for 24 to 48 h caused by metabolism of DMSO.30 DMSO 
may cause severe vasospasm that could lead to vasoconstriction if injected rapidly.1,30,38,47 
The acceptable injection rate for DMSO was found to be 0.2 mL/min, so the procedure 
takes from 1-3 h after preparation.1,48  
1.4.3. PHIL™ 
PHIL™ (Microvention, Tustin, California) was approved by the FDA in 2016 for use in 
arteriovenous malformations and hypervascular tumors.16,21 It is a non-adhesive liquid 
embolic agent comprised of a biocompatible copolymer, poly(lactide-co-glycolide) and 
poly(hydroxyethyl methacrylate) (PHEMA), covalently bonded to an iodine component 
for radio-opacity and dissolved in DMSO.16,21,23,49,50  It is commercially available at 
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concentrations of 25, 30, and 35 wt%, with viscosities of 16, 36, and 72 cSt and embolic 
capacities of 0.85, 0.87, and 0.94 mL, respectively.23 All compositions come in a pre-filled 
sterile syringe containing 1 mL of PHIL™ system that does not require prior preparation 
or shaking.21 PHIL™ produces slower backflow, reducing the risk of unintended 
embolization of proximal vessels and has an aesthetic advantage over Onyx® for use in 
AVMs in the face due to its white color. 23 PHIL™ 35% has achieved complete occlusion 
of aneurysms and complete filling of dAVFs 17,49,50 Treatment of type II endoleaks has 
been performed successfully with different combinations of PHIL™ 25%, 30% and 35%.16 
However, PHIL™ 25% is more brittle and less pliable, so it could fragment and migrate to 
nearby vessels, which may give rise to several complications or death.23 
The iodine radio-opaque agent, triiodophenol, is covalently bonded to the 
copolymer in PHIL™. Thus, there is no risk of radio-opaque agent aggregation or 
precipitation regardless of procedure time, resulting in a more homogenous fluoroscopic 
appearance and more consistent visibility as compared to Onyx®.17,21,23 Iodine as radio-
opacifier is also more advantageous during postinterventional imaging because it produces 
significantly less artifacts in CT scans and no artifacts in GRE and SWI.17,21,23 However 
PHIL™ 25% has reduced visibility as compared to Onyx® 18 in small vessels because 
iodine is less radio-opaque.17  
PHIL™ 25% has decreased injection times as compared to Onyx® because it 
precipitates faster, has a greater embolic capacity, and is benefitted from shorter pauses 
between injections.17,21,23 PHIL™ 25% precipitates within 3 minutes, as compared to 
Onyx® 18, which takes 5 min to precipitate, resulting in faster plug formation and 
procedure time. 21,23  In addition, PHIL™ has greater embolic capacity at comparable 
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viscosities; 0.25 mL of PHIL™ 25 produces the same extent of embolization as 1 mL of 
Onyx® 18.21 A study showed that shorter pauses between injections of PHIL™ 25% does 
not have adverse effects and results in better filling.21 Better forward penetration has also 
been achieved with PHIL™; the smallest vessel reported to be occluded with PHIL™ 25% 
was 2.9 micrometers in diameter.23  
Onyx® and PHIL™ are less thrombogenic than NBCA. 17 Thrombogenicity is 
desirable for complete occlusion with coils because it promotes the formation of a clot that 
fills the free space around coils.51 However, it is not desirable on liquid embolics because 
they most often achieve more homogeneous occlusion. Thrombogenicity caused by LEAs 
would likely produce adverse effects.51 Moderate vascular inflammation has been observed 
with LEAs dissolved in DMSO and accompanied by angionecrosis for Onyx®.23  
1.5. Drawbacks of Liquid Embolic Agents 
Reflux remains a major challenge among liquid embolic agents because it can be difficult 
to control. 12 Certain degree of reflux is desired for the formation of a polymeric cast “plug” 
around the catheter tip. 21,30This enables deep penetration and improves antegrade 
movement of the embolic agent, while reducing the risk of excessive reflux. 21 However, 
excessive reflux is still common and can lead to embolization of non-target arteries and 
microcatheter entrapment.21,39 In some cases, removal of entrapped microcatheters has 
resulted in intracranial hemorrhages.39 Some techniques have been studied to reduce reflux 
and in turn reduce the likelihood of microcatheter entrapment. 39  
One approach is the simultaneous use of two microcatheters to deliver Onyx®; one 
microcatheter with a detachable tip was used to deliver Onyx®, while the other one was 
used to inject NBCA to glue the detachable tip to the precipitated Onyx®.12,39 However, 
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this is not possible when the microcatheter cannot reach the feeding arteries.12 The use of 
a dual-lumen balloon catheter is another way to minimize retrograde reflux that has showed 
clinical success for the treatment of brain aneurysms, AVMs and dAVFs with 
Onyx®.12,25,37,39,52,53 For this approach, one lumen is used to inflate a balloon that prevents 
reflux, the second lumen delivers the liquid embolic agent.39 However, due to their larger 
diameter, dual-lumen catheters are limited in use to higher caliber vasculature.39 Moreover, 
balloon-assisted transvenous embolization may prevent reflux into proximal arteries, as 
opposed to embolization through the transarterial route which often produces excessive 
reflux.15 However, the transvenous route is not always accessible.15 An additional 
consideration with balloon catheters is that some may not be compatible with all liquid 
embolics, such as NBCA.39,54  
1.6. Introduction to N-isopropylacrylamide Polymers 
The thermal transition behavior of poly(N-isopropylacrylamide) (pNIPAAm) was first 
reported in 1967 by Scarpa et al.55 pNIPAAm is a thermo-responsive polymer with a lower 
critical solution temperature (LCST) capable of undergoing a reversible phase transition or 
phase separation due to its amphiphilic nature, as shown in Figure 1. This property enables 
it to be soluble in aqueous solution below the LCST without the need of toxic solvents, and 
to solidify in situ if the LCST is below body temperature. Above the LCST, hydrogen bond 
activity from the amide groups decreases due to the breaking of hydrogen bonds between 
water and the NH and CO groups.56 Consequently, hydrophobic interactions of isopropyl 
groups become dominant, resulting in a decrease in the solubility of the polymer, causing 
the polymer chains to collapse and precipitate if the concentration is sufficient.56  
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Figure 1. Chemical structure illustrating the amphiphilic nature pNIPAAm. Amide groups are 
hydrophilic, and isopropyl groups are hydrophobic. 
 
The LCST of pNIPAAm can be modified by the addition of comonomers or side 
chains that affect its hydrophilicity. The use of hydrophilic comonomers has resulted in an 
increase of the LCST.57 Similarly, the addition of hydrophobic comonomers is expected to 
decrease the LCST.58 LCST can also vary according to the average molecular weight of 
the polymer, with lower molecular weights having lower LCST as compared to higher 
molecular weights.59 In addition, higher buffer concentrations and higher pH have shown 
to decrease the LCST of pNIPAAm copolymers.60 There are several methods of reporting 
LCST values for thermo-responsive polymers. Cloud point determination uses UV-Vis 
spectroscopy to examine the turbidimetry of a polymer solution at different temperatures 
and is the most popular method of measuring the LCST of a polymer.61 It has been reported 
as the half-max absorbance value, the temperature corresponding to a 10% reduction in the 
transmittance of a solution, the temperature at the inflection point, as well as by the tangent 
method. 62 In addition, the temperature at which the first opaqueness is observed has 
previously been reported as the onset temperature and also as the LCST.63 Cloud point 
determination takes advantage of changes in turbidimetry of the solution due to 
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hydrophobic interactions, which are faster in solutions with higher polymer 
concentration.63 
1.7. Objective of the Thesis 
The objective of this thesis was to synthesize a liquid embolic agent that is dissolved in 
non-toxic solvents and degrades at the rate that tissue is regenerated. A NIPAAm-based 
copolymer was chosen due to its ability to be injectable through a catheter in aqueous 
solution and precipitate in situ, eliminating the need for a toxic solvent. Hydrophobic 
peptides that become more hydrophilic upon degradation by collagenase were chosen as 
side groups. Therefore, as cells migrate and remodel the vessel wall, the LCST of the 
polymer would increase to above body temperature and subsequently redissolve into the 
bloodstream instead of fragmenting and migrating into nearby vessels. Furthermore, this 
work investigated different hydrophobic peptides to determine which one produced the 
greatest LCST change upon degradation and the greatest mechanical stability.  
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CHAPTER 2 
THERMO-RESPONSIVE COPOLYMERS WITH ENZYME-DEPENDENT LOWER-
CRITICAL SOLUTION TEMPERATURES. 
2.1. Introduction 
N-isopropylacrylamide (NIPAAm) copolymers have a lower critical solution temperature 
(LCST) due to their amphiphilic nature, which allows them to be injectable below LCST 
and to solidify in situ above the LCST, if the concentration is sufficient, and are widely 
used in biomedical applications. 57 To decrease chronic inflammatory response in 
controlled drug delivery applications, several hydrolyzable side groups have been used in 
those biodegradable NIPAAm-based copolymers. Recently, a number of NIPAAm based 
copolymers have been developed which respond to specific biological targets such as 
enzymes, resulting in the degradation of the copolymer-based hydrogel.57,64,65 The aim of 
this study was to investigate amino acid substitution in an enzyme degradable side group 
of a NIPAAm copolymer for drug delivery and bioresorbable scaffolds for tissue 
engineering. Therefore, in this work, a series of NIPAAm-based copolymers with 
hydrophobic side groups containing the Ala-Pro-Gly-Leu collagenase substrate peptide 
sequence were synthesized as in situ forming, injectable copolymers. Collagenase is a 
matrix metalloproteinase (MMP) that plays an important role enabling cell migration and 
tissue remodelling. 64,66 The Gly-Leu peptide bond in these polypeptides is cleaved by 
collagenase, converting the side group into the more hydrophilic GAPG-COOH, thus 
increasing the LCST of the hydrogel. 57The side groups Gly-Ala-Pro-Gly-Leu-Phe-NH2 
(GAPGLF-NH2), Gly-Ala-Pro-Gly-Leu-Leu-NH2 (GAPGLL-NH2), Gly-Ala-Pro-Gly-
Leu-Val-NH2 (GAPGLV-NH2), and Gly-Ala-Pro-Gly-Leu-Phe-COOH (GAPGLF-
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COOH) were used to synthesize poly(NIPAAm-co-GAPGLF-NH2) (PNF-NH2), 
poly(NIPAAm-co-GAPGLL-NH2) (PNL-NH2), poly(NIPAAm-co-GAPGLV-NH2) 
(PNV-NH2), and poly(NIPAAm-co-GAPGLF-COOH) (PNF-COOH) copolymers. 
2.2. Methods 
2.2.1. Materials 
N-isopropylacrylamide (NIPAAm, TCI chemicals) was purified by recrystallization in 
hexane, filtered, and vacuum dried for 3 days. 2,2’-Azobisisobutyronitrile (AIBN, Aldrich) 
was purified by recrystallization in methanol. GAPGLF-NH2 (F-NH2), GAPGLL-NH2 (L-
NH2) and GAPGLV-NH2 (V-NH2) peptides were obtained from the Biodesign Institute 
(Tempe, AZ). GAPGLF-COOH (F-COOH), >95% purity, was purchased from Genscript. 
Structures of peptides are shown in Figure 2. N-acryloxysuccinimide (NASI), 
tetrahydrofuran (THF), triethylamine (TEA), and ethyl ether were obtained from Sigma 
Aldrich. 125mM HEPES and 150 mM PBS buffer solutions, pH 7.4, were used for cloud 
point measurements. 125mM HEPES + 5mM CaCl2 buffer solution and 150mM PBS 
buffer solution + 5mM CaCl2, pH 7.4, were prepared for use during enzyme degradation 
studies. Sigma blend type F collagenase from clostridium histolyticum was purchased from 
Sigma Aldrich.  
 
Figure 2. Chemical structures of (A) GAPGLF-NH2, (B) GAPGLL-NH2, (C) GAPGLV-NH2 and 
(D) GAPGLF-COOH.  
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2.2.2. Synthesis of Poly(NIPAAm-co-peptide) copolymers 
Poly(NIPAAm-co-peptide) copolymers and pNIPAAm were synthesized according to 
previous literature57, as shown in Scheme 1. Poly(NIPAAm-co-NASI) was synthesized by 
reacting NIPAAm with NASI by free radical polymerization at a molar feed ratio of 90:10 
in THF with AIBN as the initiator. The reaction was carried out under a nitrogen 
environment at 65ºC for 24 h. The product was precipitated in ethyl ether, vacuum dried, 
dialyzed (3.5 kDa MWCO) for 3 days at 4ºC and lyophilized before peptide substitution. 
Poly(NIPAAm-co-NASI) was used to synthesize pNIPAAm and poly(NIPAAm-co-
peptide) copolymers. 50-fold N-isopropylamine, and TEA, equimolar with NASI, were 
added to a 10 wt% solution of poly(NIPAAm-co-NASI) in THF and allowed to react for 
24 h to obtain pNIPAAm homopolymer. Peptide and triethylamine (TEA), equimolar with 
peptide, were added to a 10 wt% solution of poly(NIPAAm-co-NASI) in THF. The reaction 
was carried out under a nitrogen environment at 50ºC for 72 h. The remaining NASI groups 
were backreacted with 50-fold N-isopropylamine at 50ºC for 24 h to obtain poly(NIPAAm-
co-peptide) polymers. The product was then filtered to removed succinimide salts, 
precipitated in cold ethyl ether, filtered to recover the product, vacuum dried, dialyzed (3.5 
kDa MWCO) at 4ºC for 6 h and lyophilized.   
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Scheme 1. Reaction synthetic scheme for pNIPAAm and poly(NIPAAm-co-GAPGLX), where X 
is F-NH2, L-NH2, V-NH2, or F-COOH. 
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2.2.3. 1H Nuclear Magnetic Resonance  
1H NMR measurements were made with a 400 MHz Bruker spectrometer using 
10mg/750𝜇L polymer solutions in a deuterated solvent. Deuterated chloroform (CDCl3) 
and deuterium oxide (D2O) were used as solvents. 1H NMR was used to confirm the 
successful synthesis of poly(NIPAAm-co-NASI) and poly(NIPAAm-co-peptide).  
2.2.4. Enzyme Degradation 
5 wt% samples of poly(NIPAAm-co-peptide) were prepared in 125 mM HEPES or 150 
mM PBS standard buffer solutions,  pH 7.4, containing 5 mM CaCl2 and kept at 25ºC. 
Collagenase solution was prepared fresh every day at 40 mg/mL concentration and 10µL 
of it was added per 1 mL of polymer solution every day for 5 days. Control samples were 
maintained without enzyme. After 5 days, solutions were dialyzed (3.5 kDa MWCO) at 
4ºC for 3 h and lyophilized. Scheme 2 shows the enzyme degradation reaction scheme for 
poly(NIPAAm-co-peptide) copolymers. 
 
 
Scheme 2. Enzyme degradation by collagenase of poly(NIPAAm-co-GAPGLX), where X is F-
NH2, L-NH2, V-NH2, or F-COOH. 
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2.2.5. Cloud Point Determination 
LCST before and after enzyme degradation was determined by cloud point measurement 
using UV spectrophotometer by half-max and tangent method, as shown in Figure 3. 
Polymer samples were dissolved at 0.3 wt% in buffer solution. Cuvettes containing the 
polymer solutions were heated in a water bath and the relative absorbance at 450 nm was 
measured from 20 ºC to 40 ºC every 1 ºC increase, and from 40ºC to 60 ºC every 5 ºC 
increase. Each measurement was taken every 5 minutes after increasing the temperature. 
125 mM HEPES and 150 mM PBS standard buffer solutions, pH 7.4, were used for 
absorbance measurements. Cuvettes containing buffer alone were used as reference.  
 
Figure 3. Representation of LCST determination by half-max and tangent method from 
turbidimetry. 
 
Half-max Method 
In some polymer solutions, the increase in temperature causes aggregation and subsequent 
precipitation. As a result, the absorbance reaches a maximum and then continues to 
decrease as temperature is further increased.58 For other polymer solutions, the absorbance 
continues to increase as temperature is increased.58 For both cases, the LCST is determined 
as the temperature at which the curve is at 50% maximum absorbance, as shown in Figure 
3.57,67  
  
22 
Tangent Method 
This method consists of fitting two lines on the relative absorbance vs temperature curve 
obtained by UV/Vis spectroscopy. One line corresponding to the baseline before any 
increase in relative absorbance, while the other line corresponds to the tangent at the 
inflection point of the curve. The tangent method LCST is the temperature at which the 
tangent line to the inflection point and the line on the baseline intercept each other, as 
shown in Figure 3. 68,69  
2.2.6. Rheology 
Mechanical stability of the gel formed by 30 wt% polymer in 125 mM HEPES buffer 
solution (pH 7.4) was measured at 37 ºC using a Physica MCR 101 (Anton Paar) rheometer. 
Parallel plate geometry of 25 mm diameter and a 0.2 mm gap were used for the rheology 
measurements. Amplitude sweep was performed from 0.01 to 100% strain under the 
frequency of 1 Hz at 50 mN normal force. Storage moduli (G’) were reported at 0.5% 
strain. 
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2.3. Results 
2.3.1. 1H NMR 
1H NMR was used to confirm the polymerization of NIPAAm monomer with NASI. NASI 
was added as a good leaving group to be substituted by the peptide or N-isopropylamine, 
both of which become partially negative due to the presence of TEA.58 The mole ratio of 
NIPAAm and NASI was calculated from the integration ratio between the lone proton of 
the isopropyl group of NIPAAm [1H, (CH3)2CHNHCO], appearing at ~3.89 ppm, and the 
methylene protons of NASI [4H, (CH2)2(CHO)2NOCO], appearing at ~2.89 ppm, as shown 
in Error! Reference source not found.. The NASI content in poly(NIPAAm-co-NASI) 
was determined to be 7.83 mol%. The mole ratios of NIPAAm and peptide on Table 1 were 
determined by the integration ratio between the lone proton of the isopropyl group of 
NIPAAm and the methyl protons of leucine [6H, GAPG((CH3)2CHNHCO)X], appearing 
between ~0.9 and 1 ppm, as seen in Figure 4. The disappearance or reduction in the peak 
corresponding to the methyl protons of leucine confirmed the cleavage of the Gly-Leu 
bond, as seen in Error! Reference source not found.. The values in Table 1 indicated that 
the peptide content in the synthesized polymers are much lower than actual feed. The 1H 
NMR spectra of synthesized polymers are presented in Figure 10-15 in Appendix A. 
Table 1. Polymer composition, storage modulus (G’), critical strain and cross-over strain of 
poly(NIPAAm-co-GAPGLX) copolymers. 
 Peptide contenta Storage Modulusb 
(kPa) 
Critical Strainb Cross-over Strainb 
Polymer Feed Composition (%) (%) 
PNF-NH2   4% 6.10%57    
 4% 1.49% 71.9 0.6 3 
PNL-NH2 4% 0.19% 51.4 2 8 
PNV-NH2 4% 0.13% 12.9 2 7 
 8% 0.23% 14.8 1 7 
PNF-COOH 2% 0.22%    
 8% 0.76%    
aPeptide content is in mol%. 
bStorage modulus (G’) at 0.5% strain, critical strain (%) and cross-over strain (%) of poly(NIPAAm-co-
GAPGLX) copolymers at 30 wt% in 125 mM HEPES buffer solution, 7.4 pH.  
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Figure 4. 1H NMR spectra of pNIPAAm, poly(NIPAAm-co-NASI), PNF-NH2, and 
poly(NIPAAm-co-GAPG-COOH).  
 
2.3.2. Cloud Point Determination 
 
D2O 
c 
c 
1 3 
2 
a 
5 4 
c 
4,5 
2 
1,3 
1,3 
1,3 
2 
2 
b 
a 
a 
a 
1 
a 
2 
5 4 
b b 
3 
1,3 
2 
a 
CDCl3 
p(NIPAAm-co-GAPG-COOH) 
PNF-NH2 
p(NIPAAm-co-NASI) 
pNIPAAm 
  
25 
 
 
 
Figure 6-7 show the cloud point data for the copolymers synthesized. This data was used 
to determine the LCST of the copolymers. Enzyme degradation of PNF-NH2, PNL-NH2, 
PNV-NH2 and PNF-COOH copolymers was carried out in HEPES containing 5mM CaCl2. 
In addition, enzyme degradation for PNF-COOH copolymers was also done in PBS 
containing 5mM CaCl2. LCST was determined by half-max absorbance temperature (Table 
2) and tangent method (Table 3) before and after degradation.  
It was observed that doubling the amount of peptide (from 0.13 to 0.23 mol%) for 
PNV-NH2 increased the LCST by ~2 ºC (from 34.5 to 36.4 ºC) according to the half-max 
method (Table 2), and by ~1.5 ºC (from 32.0 to 33.4 ºC) as determined by the tangent 
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method (Table 3) (Figure 5). PNV-NH2 containing 0.13 mol% peptide resulted in 0.6 ºC 
LCST change (from 34.5 to 35.3 ºC), after enzyme degradation, as determined by half-max 
method (Error! Reference source not found.), which is similar to the LCST change 
calculated to be 0.7 ºC (from 32.0 to 32.7 ºC) by tangent method (Table 3)(Figure 6). PNL 
containing 0.19 mol% peptide resulted in 2.1 ºC LCST change (from 34.6 to 36.7 ºC), 
determined by half-max method (  
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Table 2), while the LCST change is 1.4 ºC (from 32.3 to 33.7 ºC) as calculated from 
tangent method (Table 3) (Figure 6). For PNF-NH2 copolymers, 4-fold increase in the 
GAPGLF-NH2 (~1.5 to 6.1 mol%) content in the copolymer results in 3.5-fold increase in 
the LCST change (from 2.5 to 8.6 ºC), according to the half-max method (  
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Table 2), whereas it results in 6-fold increase in the LCST change (from 1.6 to 9.1 
ºC) according to the tangent method (Table 3)(Figure 6). Similarly, for PNF-COOH 
copolymers, 4-fold increase in the peptide content of GAPGLF-COOH (~0.2 to 0.8 mol%) 
results in 6-fold increase in the LCST change (from 0.6 to 3.5 ºC), according to the half-
max method (  
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Table 2), whereas it results in 4-fold increase in the LCST change (from 0.4 to 1.6 
ºC), according to the tangent method (Table 3) (Figure 7). Thus, it was observed that the 
change in LCST from the tangent method differed from the LCST change calculated from 
the half-max method for PNL-NH2, PNF-NH2, and PNF-COOH, but not for PNV-NH2.  It 
also appeared that LCST change was more pronounced for PNF-COOH than for PNF-NH2, 
according to the tangent-method (Table 3), both following a linear correlation of the LCST 
change with peptide content, as seen in Figure 8. Thus, peptide content needed to produce 
the desired LCST change could be extrapolated from this graph.    
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Table 2. Half-max absorbance LCST of poly(NIPAAm-co-peptide) copolymers.  
 Peptide content 
LCST before  
degradation (ºC) 
LCST after 
degradationa(ºC) Change (ºC) 
Polymer (mol%) HEPES PBS HEPES PBS HEPES PBS 
poly(NIPAAm)  0 a,57 33.3 - 33.3 - 0 - 
 0 33.2 33.5 33.2 33.5 0 0 
PNF-NH2  
 
6.10%a,57 30.7 - 39.3 - 8.6 - 
1.49% 35.0 35.2 37.5 36.4 2.5 1.2 
PNL-NH2 0.19% 34.6 34.6 36.7 - 2.1 - 
PNV-NH2 
 
0.13% 34.5 34.8 35.3 - 0.6 - 
0.23% 36.4 36.6 - - - - 
PNF-COOH 
 
0.22% 35.3 35.5 35.9 - 0.6 - 
0.76% 36.0 36.0 39.5 - 3.5 - 
aPoly(NIPAAm) and PNF-NH2 containing 6.1 mol% peptide data obtained from Overstreet et al.57 
 
 
Table 3. Tangent method LCST of poly(NIPAAm-co-peptide) copolymers. 
 Peptide content 
LCST before 
degradation(ºC) 
LCST after 
degradation(ºC) Change (ºC)    
Polymer (mol%) HEPES PBS HEPES PBS HEPES PBS 
poly(NIPAAm)  0 a,57 29.5 - 29.5 - 0 - 
 0 32.2 32.6 32.2 32.6 0 0 
PNF-NH2a 
 
6.10%57 25.3 - 34.4 - 9.1 - 
1.49% 32.8 32.7 34.4 33.8 1.6 1.1 
PNL-NH2 0.19% 32.3 32.0 33.7 - 1.4 - 
PNV-NH2 
 
0.13% 32.0 32.5 32.7 - 0.7 - 
0.23% 33.4 34.0 - - - - 
PNF-COOH 
 
0.22% 32.9 33.5 33.3 - 0.4 - 
0.76% 33.2 33.0 34.8 - 1.6 - 
apoly(NIPAAm) and PNF-NH2 containing 6.1 mol% peptide data obtained from Overstreet et al.57 
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Figure 5. Variation of LCST depending on the peptide content in the polymers before enzyme 
degradation at 0.3 wt%.  Relative absorbance at 450 nm of PNV-NH2 copolymers with 0.1 mol% 
and 0.2 mol% in (A) HEPES and (B) PBS; PNF-COOH copolymers with 0.2 mol% and 0.8 mol% 
in (C) HEPES and (D) PBS. 
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Figure 6. Relative absorbance at 450 nm before and after enzyme degradation of (A) PNF-NH2 at 
0.3 wt% in HEPES and (B) PNF-NH2 at 0.3 wt% in PBS, (C) PNL-NH2 at 0.3 wt% in HEPES, and 
(D) PNV-NH2 at 0.3 wt% in HEPES.   
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 A 
 
 
 B 
 
 
Figure 7.  Relative absorbance at 450 nm of PNF-COOH with (A) 0.2 mol% and (B) 0.8 mol% 
peptide content before and after degradation at the polymer concentration of 0.3 wt% in HEPES. 
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Figure 8. Variation of LCST due to enzyme degradation with peptide composition in (A) PNF-
NH2 by half-max and tangent method, and (B) PNF-NH2 and PNF-COOH by tangent method. 
 
2.3.3. Rheology 
Storage (G’) and loss (G’’) moduli of 30 wt% PNF-NH2, PNL-NH2 and PNV- NH2 gels in 
HEPES buffer were obtained by amplitude sweep under the constant frequency of 1 Hz 
(Error! Reference source not found.). Rheology was done to evaluate the mechanical 
stability of PNL-NH2, PNV-NH2 and PNF-NH2. Error! Reference source not found. 
shows the strain dependence of storage (G’) and loss modulus (G’’) of the gels formed by 
30 wt% polymer. Greater G’ value than G’’ indicated the formation of gel at 37 ºC. Storage 
moduli were reported in Error! Reference source not found. at 0.5% strain, where PNL-
NH2 and PNV-NH2 samples exhibit a linear viscoelastic region at a small strain range (0.1-
1%). PNF-NH2 had the highest storage modulus at 72 kPa, as shown in Table 1. It also had 
the lowest cross-over strain, at 3% strain. The highest critical strain corresponded to PNL-
NH2 and PNV-NH2 containing 0.1 mol% peptide, at 2% strain.  
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Figure 9. Storage modulus (G’) and loss modulus (G’’) vs applied strain for (A) PNF-NH2, (B) 
PNL-NH2, (C) PNV-NH2 containing 0.1 mol% and (D) PNV-NH2 containing 0.2 mol% peptide by 
amplitude sweep under the frequency of 1 Hz at the polymer concentration of 30 wt% in HEPES. 
In each graph, blue dotted line indicates critical strain and green dotted line indicates cross-over 
strain. 
 
2.4. Discussion 
Poly(NIPAAm-co-peptide) copolymers were synthesized according to previous 
literature57, as shown on Scheme 2.  Poly(NIPAAm-co-NASI) was synthesized by free 
radical polymerization, then peptide was conjugated. Then poly(NIPAAm-co-NASI-co-
peptide) was synthesized by nucleophilic attack on the carbonyl group of NASI by the 
primary amine group of the peptide. Peptide conjugation was confirmed by the presence of 
peaks corresponding to the methyl protons of Leu, between ~0.9 ppm and ~1.0 ppm. 
Substitution of the remaining NASI by N-isopropylamine was confirmed by the absence 
of the ~2.89 ppm peak corresponding to the methylene protons of NASI as shown in  
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Figure 4. Similarly, enzyme degradation was confirmed by the absence of the peak 
corresponding to the methyl protons of leucine as seen in Error! Reference source not 
found., which suggests the cleavage of the Gly-Leu bond of the peptide.  
PNF-NH2 synthesized in previous literature with 4 mol% peptide in feed contained 
6.1 mol% peptide, as seen in Table 1. This copolymer was dialyzed against 10 kDa 
MWCO, which may have eliminated smaller chains with less or no peptide content. We 
used 3.5 kDa MWCO during our purification process, so our peptide composition as 
determined by the ratio of NIPAAm to leucine in 1H NMR spectra accounts for all the big 
as well as small  chains of pNIPAAm copolymer, which upon counting, came up to contain 
little to no peptide. In order to confirm this theory, poly(NIPAAm-co-peptide) could be 
fractionated by dialysis and 1H NMR could be used to determine if the higher molecular 
weight chains contain the most peptide. 
LCST of all the copolymers was determined by tangent and half-max methods, as 
shown in   
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Table 2 and Table 3. In the tangent method, the calculated temperature is at which 
precipitation of the polymer starts occurring in the solution. The half-max method gives a 
good indication of heterogeneity, which may arise from polydispersity in molecular weight 
or peptide conjugation in the copolymers. Chains will precipitate at different temperatures 
according to their composition. Lower molecular weight chains will precipitate at lower 
temperatures.59 Chains with higher peptide content before degradation will likely 
precipitate at lower temperatures, due to the hydrophobic nature of the peptides.57 
Likewise, after enzyme degradation, chains with higher peptide content will likely 
precipitate at higher temperatures due to the hydrophilic nature of the carboxylic acid 
termination in the peptide after degradation.60 Using a 3.5 kDa MWCO dialysis bag likely 
resulted in heterogeneous copolymers, as seen from the LCST difference of 2 to 3 ºC of 
the copolymers before degradation calculated by half-max and tangent method (  
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Table 2 and Table 3). This heterogeneity could be reduced by using a higher 
MWCO dialysis bag, which would result in similar half-max and tangent LCST values. 
It was observed that the change in LCST obtained by the half-max method (Table 
2) differed from the tangent method change in LCST (Table 3) for PNL-NH2, PNF-NH2, 
and PNF-COOH, but not for PNV-NH2, which suggests the heterogeneity of the PNL-NH2, 
PNF-NH2, and PNF-COOH. Also, this suggests that PNV-NH2 containing 0.13 mol% 
peptide may be more homogeneous, which could be due to its lower peptide conjugation 
as compared to PNF-NH2, and PNF-COOH. Both PNL-NH2 and PNV-NH2 had ~0.2 mol% 
peptide content, but Leu is more hydrophobic than Val, due to its extra methylene group, 
as shown in Figure 2. Therefore, the LCST of PNL-NH2 (32 ºC) before degradation was 
lower than that of PNV-NH2 (34 ºC). The LCST of PNL-NH2 is also lower than pNIPAAm 
(32.6 ºC), which shows that the hydrophobicity of Leu was significant to lower the LCST 
at 0.2 mol% peptide content.  
Enzyme degradation was carried out in two different buffer solutions containing 
calcium salt for the activation of collagenase for PNF-NH2. Half-max LCST data in Error! 
Reference source not found. shows that the change in LCST was greater in HEPES as 
compared to PBS for PNF-NH2, suggesting that the higher buffer concentration in PBS 
affected the LCST of PNF-NH2 after degradation. . This result is consistent with previous 
work that has shown that higher buffer concentration lowers the LCST of p(NIPAAm) 
copolymers.60,70 Dissolution of copolymers in water has to compete with that of the charged 
entities of buffer. Furthermore, inter/intra molecular hydrogen bonding complexes between 
carboxylic acid from GAPG-COOH and amide groups are favored, producing a lower 
LCST.60 A way to determine if buffer strength affects the state of the copolymer chain after 
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degradation would be by dynamic light scattering (DLS), which would determine if the 
polymer dissolved in 150 mM PBS has a larger hydrodynamic diameter as compared to 
when dissolved in 125 mM HEPES. A larger size would correspond to the size of the 
aggregates formed by the polymer while in the globule state, as compared to the chains 
being in the coil state.70  
Enzyme degradation was also carried out in HEPES containing calcium salt for 
PNL-NH2, PNV-NH2 containing 0.13 mol% peptide, and PNF-COOH copolymers. Cloud 
point data obtained indicates that LCST increases after enzymatic degradation for all 
copolymers, suggesting the conversion of poly(NIPAAm-co-GAPGLX) to the hydrophilic 
poly(NIPAAm-co-GAPG-COOH). Importantly, the highest LCST after degradation 
corresponds to the polymers with the highest initial peptide content. These polymers will 
have the greatest amount of GAPG-COOH, resulting in a greater LCST. The next step 
would be to investigate enzyme kinetics and compare across all copolymers.  
Rheology of the polymer gels provide the information about G’, critical strain and 
cross-over strain (Table 1). G’ values depicts the mechanical stability of the gels; critical 
strain values show the strain at which the network structure would start getting disrupted 
and cross-over strain is the strain at which the material would start to flow. Past the cross-
over strain, the copolymers could be deliverable through a catheter at 37ºC, as shown in 
Figure 9. This demonstrates that the gels are shear-thinning due to the physical crosslinking 
associated with pNIPAAm copolymers. Physical crosslinks of these gels at 30 wt% are 
disturbed between 0.6 and 2% strain and broken at 3% for PNF-NH2 and at 7-8% for PNL-
NH2 and PNV-NH2 copolymers. G’ values indicated that PNF-NH2 has the greatest 
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mechanical stability of all the gels and doubling of peptide content in PNV-NH2 did not 
change its mechanical stability. 
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CHAPTER 3 
CONCLUSION AND FUTURE WORK 
3.1. Conclusion 
A series of enzyme degradable NIPAAm based copolymers was successfully synthesized 
and characterized. Cloud point and 1H NMR data suggest the cleavage of the Gly-Leu 
peptide bond by collagenase in HEPES buffer, converting the copolymers to 
poly(NIPAAm-co-GAPG-COOH). According to the literature and based on our research, 
increase in the peptide content in the copolymer makes it more prone to enzyme 
degradation, causing increase in the LCST of the copolymer after degradation. PNF-NH2 
had the greatest peptide conjugation success, and rheology data suggests that it also has the 
highest mechanical stability, which is crucial for liquid embolic agents. Hence, F-NH2 
showed the greatest potential for producing a mechanically stable liquid embolic agent that 
could attain a change in LCST to above body temperature upon degradation. Enzymatic 
degradation property and moderate mechanical stability convinces the use for these 
copolymers for endovascular embolization.  
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3.2. Future Work 
3.2.1. Optimization of Peptide Substitution 
Our study demonstrated the successful conjugation of NASI to NIPAAm. However, the 
nucleophilic substitution of NASI in P(NIPAAm-co-NASI) by the peptide needs 
optimization. Some insight could be gained by investigating the reaction kinetics of this 
nucleophilic substitution reaction, while varying the amount of TEA added to the reaction, 
the temperature at which the reaction proceeds, and solubilization of the peptide in reaction 
solvent. The addition of more TEA could increase the rate at which NASI gets substituted 
by the peptide, possibly shifting the reaction from 1st to 2nd order reaction, In first order 
reactions, the reaction slows down as the amount of reagent, in this case peptide, is reduced, 
while second order reactions are not as dependent on the amount of reagent left as the 
reaction proceeds. In addition, alternative methods to measure peptide content should be 
explored, due to the difficulty of accurately integrating the peaks corresponding to the 
peptide by NMR. Mass spectrometry has been used to quantify the peptide content in 
polymer-peptide copolymers71,72 and may be useful for this application.  
3.2.2. Incorporation of Cell-adhesive Peptides 
Cell-adhesive peptides in hydrogels have shown improved cellular attachment, migration, 
and proliferation for a variety of cell types. 73,74 Peptides based on the Arg-Gly-Asp (RGD) 
sequence enable cell attachment by binding to integrin receptors that are present on the cell 
surface.74,75 This peptide is derived from fibronectin, which is a cell-adhesive component 
of the extracellular matrix (ECM).75 Cell adhesion strength of Gly-Arg-Gly-Asp-Ser 
(GRGDS) has been previously determined to be much higher than RGD. 73,76 Incorporation 
of cell-adhesive peptide GRGDS will positively impact cell survival, proliferation, and 
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migration of most adherent cells. Adhesion of integrins present in endothelial cells to RGD 
causes these cells to acquire a migratory phenotype and rebuild or form new blood 
vessels.77 This would favor remodelling of the parent artery, closing blood flow access to 
an aneurysm, AVM or hypervascular tumor. The conjugation of GRGDS in conjunction to 
GAPGLX to NIPAAm will render an injectable copolymer that is enzyme-degradable in 
addition to cell-adhesive, resulting in poly(NIPAAm-co-GAPGLX-co-GRGDS) 
copolymers. 
3.2.3. Differential Scanning Calorimetry 
LCST values obtained by cloud point determination varied greatly between tangent and 
half-max methods, providing an inconsistent point of comparison. Furthermore, it has been 
shown that the LCST reported values are affected by polymer concentration and molecular 
weight when measured by cloud point.68,69 Another way of determining LCST that is not 
affected by those variables is by differential scanning calorimetry (DSC). This method 
would provide a more consistent comparison of LCST before and after degradation among 
different peptide compositions. The temperature corresponding to the maximum of the 
endothermic peak is typically reported as the LCST, while the start of the same peak is 
referred to as the onset. 57,67 
3.2.4. Analysis of Thermo-responsive Gelation 
Another way to measure the temperature at which the polymer transitions from soluble to 
insoluble is by investigating the temperature at which the polymer transitions from being 
in solution to a gel. A thermo-responsive gelation test could better predict if the polymer 
would be soluble in aqueous solution after degradation. This is important to determine if 
the polymer would redissolve into the bloodstream after degradation to prevent 
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fragmentation that could result in the unwanted occlusion of nearby vessels. The polymer 
concentration should be sufficient to form a gel, often greater than 30 wt%, therefore 
requiring a greater amount of sample as compared to LCST determination methods, which 
require a concentration between 0.1-1 wt%.78 The tube inversion test and rheology are two 
methods by which the phase separation behavior can be studied in this class of polymers. 
The tube inversion test is widely used to determine the gelation of a polymer solution. The 
results from this study is highly dependent on concentration, heating method and tube 
dimensions.79 For this method, the solution is placed in a tube or vial, heated at small 
increments and maintained at that temperature for a specified amount of time.80 The tube 
is inverted at each temperature until reaching the temperature at which it is no longer in 
solution and has formed a gel with no visual flow.81 Rheology can also be used to study 
the sol-gel transition of a polymer. This is done by temperature sweep test at an amplitude 
of strain within the linear region of the polymer at increasing temperatures. The gelation 
temperature is at the crossover between the storage modulus (G’) and the loss modulus 
(G’’); the polymer is considered a gel when G’ is higher than G’’.81   
3.2.5. Swelling Testing 
The thermo-responsive mechanism of pNIPAAm results in the exertion of aqueous solution 
from the material. This could have affected the rheology results; a material that shrinks 
more will show a higher storage modulus. Swelling testing will help determine if PNF-
NH2 is more mechanically stable independent of shrinking. In addition, deswelling could 
potentially result in long procedure times when delivering a considerable amount of 
material to the site, as would be the case for large aneurysms. It has been demonstrated that 
the addition of Jeffamine® M-1000 can control shrinking associated with the precipitation 
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of pNIPAAm.82 In addition, swelling of the material after delivery is not ideal because it 
would exert force on the vessel wall, potentially leading to rupture and hemorrhage. It has 
been previously shown that the addition of hydrophobic monomers in pNIPAAm decreases 
the swelling of the polymer by decreasing its affinity for water caused by hydrophobic 
interactions.83 Therefore, swelling could be minimized by the hydrophobic peptides studied 
in this work. The amount of GAPGLX peptide should be optimized to produce the desirable 
LCST change after degradation, as well as to produce the desirable polymer hydrophobicity 
needed to prevent swelling of the material at the embolization site.  
3.2.6. Creep Resistance 
A liquid embolic agent must be resistant to creep in response to constant stresses from 
blood flow. For applications in aneurysms, the material will be exposed to constant stress 
from blood flow. Therefore, additional mechanical testing should be done to ensure it is 
resistant to creep under a constant shear stress. The addition of hydrophobic segments has 
been shown to increase shear and creep strength of hydrogels.57,84 Hence, GAPGLX 
peptides may also contribute to creep resistance. The addition of chemical crosslinks may 
also increase its mechanical stability and creep resistance due to the elasticity associated 
with chemical crosslinking.58 Acrylate groups attached to the end of the peptide will enable 
these copolymers to chemically crosslink with thiols present in pentaerythritol tetrakis (3-
mercaptopropionate) (QT) in aqueous solution by Michael-addition. 85–89 Thus, resulting 
in dual physically and chemically crosslinked poly(NIPAAm-co-GAPGLX-co-GRGDS-
Ac)/QT copolymers that are mechanically stable, bioactive, and enzyme-degradable for 
endovascular embolization.   
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APPENDIX A 
1H NMR Spectra of Synthesized Copolymers 
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Figure 10. 1H NMR spectrum of poly(NIPAAm-co-GAPGLF-NH2). 
 
 
 
Figure 11. 1H NMR spectrum of poly(NIPAAm-co-GAPGLL-NH2). 
 
  
57 
 
 
Figure 12. 1H NMR spectrum of poly(NIPAAm-co-GAPGLV-NH2) with 4 mol% peptide in feed. 
 
 
 
 
Figure 13. 1H NMR spectrum of poly(NIPAAm-co-GAPGLV-NH2) with 8 mol% peptide in feed. 
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Figure 14. 1H NMR spectrum of poly(NIPAAm-co-GAPGLF-COOH) with 2 mol% peptide in 
feed. 
 
 
 
 
Figure 15. 1H NMR spectrum of poly(NIPAAm-co-GAPGLF-COOH) with 8 mol% peptide in 
feed. 
 
